Chimerix, Inc. (CMRX)
Apr 21, 2025 - CMRX was delisted (reason: acquired by JAZZ)
8.54
-0.01 (-0.12%)
Inactive · Last trade price on Apr 17, 2025

Company Description

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States.

Its product pipeline comprising dordaviprone (ONC201), which is in phase 3 clinical-stage development for H3 K27M-mutant diffuse glioma, as well as in phase 2 Investigator Initiated Clinical Trials for multiple oncology studies; and ONC206, a second generation imipridone ClpP agonist and DRD2 antagonist which is in phase 1 clinical trial to treat central nervous systems and other solid tumors.

The company also develops ONC212, an imipridone, investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP, which is in preclinical trial; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of novel coronaviruses.

In addition, it offers TEMBEXA, a lipid conjugate which acts via inhibition of viral DNA synthesis that is a medical countermeasure for smallpox.

The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox.

Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Chimerix, Inc.
Chimerix logo
CountryUnited States
Founded2000
IPO DateApr 11, 2013
IndustryBiotechnology
SectorHealthcare
Employees79
CEOMichael Andriole

Contact Details

Address:
2505 Meridian Parkway, Suite 100
Durham, North Carolina 27713
United States
Phone919 806 1074
Websitechimerix.com

Stock Details

Ticker SymbolCMRX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001117480
CUSIP Number16934W106
ISIN NumberUS16934W1062
Employer ID33-0903395
SIC Code2834

Key Executives

NamePosition
Michael T. Andriole M.B.A.Chief Executive Officer, President and Director
Dr. Michael A. Alrutz J.D., Ph.D.Senior Vice President, General Counsel and Corporate Secretary
Dr. Allen S. Melemed M.B.A., M.D.Chief Medical Officer
Michelle LaSpalutoChief Financial Officer
Thomas J. RigaChief Operating and Commercial Officer
Dr. Roy W. Ware M.B.A., Ph.D.Chief Manufacturing and Technology Officer
Dr. Joshua E. Allen Ph.D.Chief Scientific Officer

Latest SEC Filings

DateTypeTitle
Apr 21, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Apr 21, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Apr 21, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Apr 21, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Apr 21, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Apr 21, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Apr 21, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Apr 21, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Apr 21, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Apr 21, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments